Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK.
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Br J Surg. 2019 Jan;106(1):13-22. doi: 10.1002/bjs.11026.
Endovascular intervention has emerged as a potential alternative to open surgery in treating common femoral artery (CFA) atherosclerotic disease. The aim of this systematic review was to assess the safety and efficacy of both techniques.
Thirteen electronic databases from 1980 to 3 January 2018 were searched. Study quality was assessed using the National Institute for Health and Care Excellence Interventional Procedure Programme quality assessment tool. Safety and efficacy outcome measures were analysed.
Thirty-one studies reporting 813 endovascular procedures and 3835 endarterectomies were included. Only two small RCTs have been reported. The methodological quality of available studies was generally low and follow-up short. Safety endpoint assessment revealed a similar risk of wound haematoma for endovascular intervention and endarterectomy (5·5 (95 per cent c.i. 0·2 to 17·2) versus 3·9 (1·7 to 6·9) per cent respectively), a lower risk of wound infection with endovascular procedures (0 versus 5·9 (3·4 to 9·0) per cent) and a lower risk of wound lymph leakage (0 versus 5·7 (3·3 to 8·6) per cent). Efficacy endpoint assessment at 1 year identified that endovascular intervention had a lower primary patency rate than endarterectomy (78·8 (73·3 to 83·8) versus 96·0 (92·2 to 98·6) per cent respectively), a higher revascularization rate (16·0 (6·1 to 29·4) versus 5·8 (1·0 to 14·2) per cent) and a similar amputation rate (2·7 (1·2 to 4·8) versus 1·9 (0·7 to 3·8) per cent).
Endovascular intervention of CFA disease appears to reduce the risk of wound complications but is associated with a lower patency rate and increased rates of subsequent revascularization procedures. Standardization of the endovascular technique and quantification of the proportions of patients suitable for either technique are required.
腔内介入治疗已成为治疗股总动脉(CFA)动脉粥样硬化疾病的一种有潜力的替代开放手术的方法。本系统综述旨在评估这两种技术的安全性和有效性。
从 1980 年至 2018 年 1 月 3 日检索了 13 个电子数据库。使用国家卫生与保健卓越研究所(NICE)介入性操作方案质量评估工具评估研究质量。分析了安全性和有效性结局指标。
纳入了 31 项研究,共报道了 813 例腔内介入治疗和 3835 例动脉内膜切除术。仅有两项小的 RCT 被报道。现有研究的方法学质量普遍较低,随访时间较短。安全性终点评估显示,腔内介入治疗和动脉内膜切除术的伤口血肿风险相似(分别为 5.5%(95%可信区间 0.2 至 17.2%)和 3.9%(1.7 至 6.9%)),腔内介入治疗的伤口感染风险较低(0 与 5.9%(3.4 至 9.0%)),伤口淋巴漏风险较低(0 与 5.7%(3.3 至 8.6%))。1 年时的有效性终点评估显示,腔内介入治疗的初始通畅率低于动脉内膜切除术(分别为 78.8%(73.3 至 83.8%)和 96.0%(92.2 至 98.6%)),再血管化率较高(16.0%(6.1 至 29.4%)和 5.8%(1.0 至 14.2%)),截肢率相似(2.7%(1.2 至 4.8%)和 1.9%(0.7 至 3.8%))。
腔内治疗 CFA 疾病似乎降低了伤口并发症的风险,但与较低的通畅率和随后血管重建手术率较高相关。需要标准化腔内技术并确定适合这两种技术的患者比例。